At more than $200 per share bid, CVS Health is reportedly in negotiations to buy the health insurance giant Aetna.
At more than $200 per share bid, CVS Health is reportedly in negotiations to buy the health insurance giant Aetna. According to The Wall Street Journal, the total deal is worth more than $66 billion.
The merger could mean the 46.7 million Aetna members could access convenient MinuteClinics run by CVS Health in its stores, in addition to the company’s retail pharmacies. It’d also give members the opportunity for improved care coordination.
If the merger is realized, CVS would wield a significant dominance within the healthcare world, being the largest retail pharmacy chain in the United States, a pharmacy benefit manager (PBM), and potentially one of the largest health insurance businesses. However, the 2 companies could face legal roadblocks, considering recent challenges faced by such announcements—a federal judge ruling blocked the Aetna—Humana ($34 billion) and Anthem–Cigna ($54 billion) mergers earlier this year.
"A monopoly of our healthcare system is not good for any American. We are very concerned about CVS Health acquiring Aetna and the adverse impact that this will have on cancer patients," said Ted Okon, MBA, executive director of the Community Oncology Alliance, in an e-mail. "CVS controls the largest PBM, a national chain of pharmacies, a mail order pharmacy, and a medical plan sponsor. As it is, cancer patients experience delays in getting critical therapy, switched treatment without their physicians’ knowledge, and higher medication costs. It will be a disaster if CVS is now allowed to control one of the largest national insurers." Okon worries that the merger will further drive up healthcare costs for average Americans.
For CVS, this deal might also be in preparation for Amazon’s foray into the pharmaceutical business, following rumors last month that the retail giant was talking to mid-size pharmacy benefit managers for contracts.
At market close on Thursday, which was when The Journal posted the news, Aetna shares climbed almost 12% while CVS saw a drop of about 3%.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More